Coming Soon: AntiViral Gel in Condoms to Kill HIV Virus
By Smitha Nambiar | July 22, 2014 4:50 PM EST
Antiviral VivaGel in Ansell condoms, which is capable of inactivating 99.9 per cent of HIV virus, will be available in the Australian market within few months. The special technology has been designed by Australian biotechnology firm Starpharma.
Students receive free condoms at an event organised by the United Nations Population Fund (UNFPA) on World Population Day in Manila July 11, 2014.
Starpharma, a biotechnology firm, based out of Australia has received Therapeutic Goods Administration approval for its special anti viral gel technology. The gel, to be used in Ansell condoms, has an antiviral compound, which can inactivate 99.9 per cent of sexually transmitted diseases like HIV, herpes and human papilloma virus. The gel falls under Ansell's LifeStyle Dual Protect line. However, the doctors have made it clear that the gel is not "foolproof," and cannot guarantee 100 per cent protection against HIV virus.
Speaking about the new antiviral gel, Dr Jackie Fairley, Starpharma's chief executive, told ABC Australia, "Anything that you can do to reduce the number of virus particles by inactivating them with a substance like VivaGel would reduce the overall viral load. The more viral particles you're exposed to, that typically translates into a greater chance of infection." Fairley further added, "There is a final step, which is a relatively rapid step which is likely to be a matter of a few weeks for listing on the ARTG."
Stating that Starpharma would receive royalties from sales of Ansell condoms using the new anti-viral VivaGel, Peter Carroll, who heads the Ansell's Sexual Wellness Global Business Unit, said, "Our partnership with Starpharma is a great example of two highly innovative Australian businesses working together to bring to market a ground-breaking new sexual health product." He further added, "New product development is central to Ansell's business strategy and this highly innovative product is exciting for both companies."
VivaGel got approval from the U.S. Food and Drug Administration for clinical trials for bacterial vaginosis only last week. Though the makers claim that the gel has antibacterial properties, the recent approval was based only on the virus it was tested against.
To contact the editor, e-mail:
Join the Conversation
- Woman Claiming To Be Former NASA Employee Says She Saw Humans Walking On Mars In 1979
- More Artefacts Found in Greece's Mystery Tomb
- 'Meatspace': Lamb Chop Sent Into Space Returns To Earth [Watch Video]
- Dinosaur Discovery 2014: New Dinosaur Species Found Inside A Canadian Museum
- Underwater Robotics Measures Thickness Of Antarctic Sea Ice
- Target’s ‘Surprise Doorbusters’ Black Friday 2014 Deals On TV Sets, Entertainment Centres, DVD Players And More
- IKEA Black Friday 2014 Ad Includes Discounts On Home Furnishings, Appliances, Kitchen Designs, Beds, Sofas, Mattresses And Toys
- T-Mobile’s Black Friday 2014 Deals On Apple iPhone 6, Samsung Galaxy Note 4/Edge, Nexus 6, HTC One M8, LG G3, iPad Air 2 And Mini 3
- 5 Proofs Russia is Geared-Up for Shooting War with U.S. and Can Win Future Nuclear Showdown
- Black Friday And Cyber Monday Sale 2014: AT&T's Cricket Wireless Offers Discounts On Lumia 1320, Galaxy S5, S4 And HTC Desire 510
- ISIS Kidnaps Iraqi Defence Minister’s Family, Executes Female Parliament Candidates
- ISIS Drug Transit From Afghanistan To Europe Confirmed By Russia: Money Goes Into Terror Funding And In New Recruitments